Nicolas Richard

Rouen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.

Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: June 28, 2026

Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.

Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: June 09, 2026

Association of bowel urgency, disease activity and disability in patients with inflammatory bowel disease: A cross-sectional study from the GETAID.

Association of bowel urgency, disease activity and disability in patients with inflammatory bowel disease: A cross-sectional study from the GETAID.

Journal: Clinics and research in hepatology and gastroenterology

Published: May 08, 2026

Incidence and Neoplastic Risk Associated with Colonic Stricture in Paediatric-Onset Crohn's Disease: A Population-based Study.

Incidence and Neoplastic Risk Associated with Colonic Stricture in Paediatric-Onset Crohn's Disease: A Population-based Study.

Journal: Clinics and research in hepatology and gastroenterology

Published: March 03, 2026

One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.

One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.

Journal: Alimentary pharmacology & therapeutics

Published: February 17, 2026

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

Journal: Journal of Crohn's & colitis

Published: September 10, 2025

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.

Journal: Anaesthesia, critical care & pain medicine

Published: July 30, 2025

Impact of Endometriosis on the Progression of Inflammatory Bowel Diseases: A Multicenter Retrospective Study.

Impact of Endometriosis on the Progression of Inflammatory Bowel Diseases: A Multicenter Retrospective Study.

Journal: Clinical and translational gastroenterology

Published: May 14, 2025

Natural History of Anal Strictures in Pediatric-Onset Crohn's Disease: Long-term Follow-up of a Population-Based Study.

Natural History of Anal Strictures in Pediatric-Onset Crohn's Disease: Long-term Follow-up of a Population-Based Study.

Journal: Diseases of the colon and rectum

Published: April 29, 2025

Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' Reply.

Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: March 31, 2025

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.

Journal: Alimentary pharmacology & therapeutics

Published: March 31, 2025

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease.

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease.

Journal: Inflammatory bowel diseases

Published: January 24, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026